Status:
COMPLETED
Safety and Immunogenicity of a Live-attenuated Universal Flu Vaccine Followed by an Inactivated Universal Flu Vaccine
Lead Sponsor:
PATH
Collaborating Sponsors:
Icahn School of Medicine at Mount Sinai
Children's Hospital Medical Center, Cincinnati
Conditions:
Influenza
Vaccine
Eligibility:
All Genders
18-39 years
Phase:
PHASE1
Brief Summary
The clinical study will evaluate safety and the immune response of a prime- boost regimen with a live attenuated influenza vaccine (LAIV) prime and an inactivated split influenza vaccine (IIV) boost w...
Detailed Description
This is a prospective, multi-center, randomized, controlled, observer-blind, Phase 1 trial in healthy male and female adults 18 through 39 years of age to evaluate safety and the immune response of a ...
Eligibility Criteria
Inclusion
- Able to understand planned study procedures and demonstrate comprehension of the protocol procedures and knowledge of study by passing a written examination prior to vaccination.
- In the opinion of the investigator, can and will comply with the requirements of the protocol (e.g., completion of the diary cards, return for follow-up visits).
- Written informed consent obtained from the subject prior to performance of any study specific procedure.
- Male or non-pregnant female between, and including, 18 and 39 years of age at the time of the first vaccination.
- Healthy subjects without acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality\*.
- Female subjects of non-childbearing potential may be enrolled in the study.
- Female subjects of childbearing potential must have a negative pregnancy test within 24 hours of vaccination.
- Female subjects of childbearing potential must have practiced adequate contraception for 30 days prior to first vaccination and agree to continue adequate contraception until 2 months after completion of the vaccination series (Month 5).
- Male subjects must be surgically sterile (e.g., vasectomy) or agree to practice adequate contraception from the first vaccination until 2 months after completion of the vaccination series (Month 5). Please refer to the glossary of terms for the definition of adequate contraception.
Exclusion
- Use of any investigational or non-registered product (drug or vaccine) other than the study vaccines.
- Any medical condition that in the judgment of the investigator would make intramuscular injection unsafe.
- Medically diagnosed deviated nasal septum or nasal obstruction.
- Chronic administration (defined as more than 14 days in total) of immunosuppressants or other immune-modifying drugs within 6 months before the first dose.
- Administration of long-acting immune-modifying drugs (e.g., infliximab, rituximab) within 6 months before the first dose (Visit 03), or planned administration any time during the study period.
- Planned administration/administration of a vaccine not foreseen by the study protocol in the period starting 30 days before the first dose (Visit 03) up to Month 15 (Visit 15)
- Persons who should be annually vaccinated against influenza who live with or care for persons at high risk for influenza-related complications.
- History of influenza vaccination within 6 months prior to study enrollment or unwillingness to forego seasonal influenza vaccination during the entire study period.
- History of vaccination with an investigational pandemic influenza vaccine other than an 2009 H1N1 Pandemic (H1N1pdm09) vaccine.
- Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.
- Infection with human immunodeficiency virus regardless of clinical stage of immunodeficiency.
- History of current infection with hepatitis B virus or hepatitis C virus regardless of clinical presentation.
- History of or current autoimmune disease.
- Subjects diagnosed with excessive daytime sleepiness or narcolepsy; or history of narcolepsy in a subject's parent or sibling.
- History of Guillain-Barré syndrome.
- History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccines (including egg proteins); a history of anaphylactic-type reaction to consumption of eggs; or a history of severe adverse reaction to a previous influenza vaccine.
- Hypersensitivity to latex.
- Administration of immunoglobulins and/or any blood products during the period starting 3 months before the first dose of study vaccines or planned administration during the study period.
- Pregnant or lactating female.
- Female planning to become pregnant or male planning to father a child or either planning to discontinue contraceptive precautions.
- Current smoker.
- During screening, have a positive test for opiates without a prescription.
- History of chronic alcohol consumption and/or drug abuse as deemed by the investigator to render the potential subject unable/unlikely to provide accurate safety reports.
- Have a history of convulsions or encephalomyelitis within 90 days prior to study vaccination.
- Have any diagnosis, current or past, of schizophrenia, bipolar disease, or other psychiatric diagnosis that may interfere with subject compliance or safety evaluations.
- Have been hospitalized for psychiatric illness, history of suicide attempt, or confinement for danger to self or others within 10 years prior to study vaccination.
- Blood donation or planned blood donation within 30 days prior to the study vaccination through 30 days after the last blood drawn for this study.
- Have signs or symptoms that could confound or confuse assessment of study vaccine reactogenicity.
- Any hematological or biochemical parameter that is out of range of normal, and is considered clinically significant by the investigator.
Key Trial Info
Start Date :
October 10 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 9 2019
Estimated Enrollment :
65 Patients enrolled
Trial Details
Trial ID
NCT03300050
Start Date
October 10 2017
End Date
August 9 2019
Last Update
February 21 2021
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Duke University
Durham, North Carolina, United States, 27710
2
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, United States, 45229